Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer
T Williamson, TB Mendes, N Joe… - Endocrine-related …, 2020 - erc.bioscientifica.com
The most common thyroid malignancy is papillary thyroid cancer. While a majority respond
to therapy and have a favorable prognosis, some papillary thyroid cancers persist. This …
to therapy and have a favorable prognosis, some papillary thyroid cancers persist. This …
Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib
WJ Wei, CT Shen, HJ Song, ZL Qiu… - Oncology …, 2016 - spandidos-publications.com
Abstract Treatment options for advanced metastatic or progressive thyroid cancers are
limited. Although targeted therapy specifically inhibiting intracellular kinase signaling …
limited. Although targeted therapy specifically inhibiting intracellular kinase signaling …
Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression
D Champa, MA Russo, XH Liao, S Refetoff… - Endocr Relat …, 2014 - erc.bioscientifica.com
Poorly differentiated tumors of the thyroid gland (PDTC) are generally characterized by a
poor prognosis due to their resistance to available therapeutic approaches. The relative …
poor prognosis due to their resistance to available therapeutic approaches. The relative …
An In Vivo Mouse Model of Metastatic Human Thyroid Cancer
Background: Mouse models of metastatic human cancers are important tools in preclinical
studies for testing new systematic therapies and studying effectors of cancer metastasis. The …
studies for testing new systematic therapies and studying effectors of cancer metastasis. The …
[HTML][HTML] Obatoclax and LY3009120 efficiently overcome vemurafenib resistance in differentiated thyroid cancer
WJ Wei, ZK Sun, CT Shen, HJ Song, XY Zhang… - Theranostics, 2017 - ncbi.nlm.nih.gov
Although the prognosis of differentiated thyroid cancer (DTC) is relatively good, 30-40% of
patients with distant metastases develop resistance to radioactive iodine therapy due to …
patients with distant metastases develop resistance to radioactive iodine therapy due to …
[HTML][HTML] mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib
EK Hanly, RB Bednarczyk, NY Tuli, AL Moscatello… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Abstract Treatment options for advanced metastatic thyroid cancer patients are limited.
Vemurafenib, a BRAFV600E inhibitor, has shown promise in clinical trials although cellular …
Vemurafenib, a BRAFV600E inhibitor, has shown promise in clinical trials although cellular …
Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway
AK Samadi, J Bazzill, X Zhang, R Gallagher, H Zhang… - Surgery, 2012 - Elsevier
Background Despite development of current targeted therapies for medullary thyroid cancer
(MTC), long-term survival remains unchanged. Recently isolated novel withanolide …
(MTC), long-term survival remains unchanged. Recently isolated novel withanolide …
[HTML][HTML] Beta-elemene inhibits differentiated thyroid carcinoma metastasis by reducing cellular proliferation, metabolism and invasion ability
L Zhao, J Wei, S Wang, T Lang, X Shi… - Annals of …, 2020 - ncbi.nlm.nih.gov
Background Accelerated glycolysis is a characteristic of carcinoma. The herb-derived
compound, beta (β)-elemene, has shown promising anticancer effects against various …
compound, beta (β)-elemene, has shown promising anticancer effects against various …
Synergistic effect of metformin and vemurufenib (PLX4032) as a molecular targeted therapy in anaplastic thyroid cancer: an in vitro study
L Durai, S Ravindran, K Arvind, D Karunagaran… - Molecular Biology …, 2021 - Springer
Background Survival rate of patients affected with anaplastic thyroid carcinoma (ATC) is less
than 5% with current treatment. In ATC, BRAF V600E mutation is the major mutation that …
than 5% with current treatment. In ATC, BRAF V600E mutation is the major mutation that …
[HTML][HTML] Effect of metformin alone and in combination with etoposide and epirubicin on proliferation, apoptosis, necrosis, and migration of B-CPAP and SW cells as …
G Ghavami, RE Kiasari, F Pakzad… - Research in …, 2023 - journals.lww.com
Background and purpose: There has not been a comprehensive study on the simultaneous
effects of metformin, etoposide, and epirubicin on thyroid cancer cells. Hence, the current …
effects of metformin, etoposide, and epirubicin on thyroid cancer cells. Hence, the current …